Mittal Medha, Yadav Vineeta, Khadgawat Rajesh, Kumar Manish, Sherwani Poonam
Department of Pediatrics, Chacha Nehru Bal Chikitsalaya, Geeta Colony, New Delhi, India.
Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):760-765. doi: 10.4103/ijem.IJEM_84_18.
To compare efficacy and safety of 90,000 IU versus 300,000 IU oral single dose vitamin D for treatment of nutritional rickets.
Randomized controlled trial.
Tertiary care hospital.
One hundred ten children (6 months to 5 years, median age 10.5 months) with rickets. Exclusion criteria were disease affecting absorption, intake of calcium/vitamin D preparation in last 6 months, abnormal renal function, and rickets other than nutritional.
Vitamin D3 as a single oral dose 90,000 IU (group A, = 55) or 300,000 IU (group B, = 55).
Severity of rickets was scored on knee and wrist X-ray as per Thacher's radiographic score. Baseline serum levels of calcium, SAP, 25(OH)D, iPTH were measured. Follow up was done at 1 week, 4 weeks, and 12 weeks.
Primary - Radiographic score at 3 months. Secondary - Serum levels of 25(OH)D, SAP, and iPTH at 3 months, clinical and biochemical adverse effects.
Eighty-six subjects (43 in each group) completed the study. The radiographic score reduced from 6.90 to 0.16 in group A and from 6.93 to 0.23 in group B. The levels of 25(OH)D, ALP, and PTH were similar between the groups at baseline and follow up. Hypercalciuria and hypercalcemia were seen more often in group B as was hypervitaminosis D. There were no clinical adverse events.
Single oral dose vitamin D3 90,000 IU is safe and effective in achieving healing of rickets.
比较口服单剂量90,000国际单位与300,000国际单位维生素D治疗营养性佝偻病的疗效和安全性。
随机对照试验。
三级医疗医院。
110名患有佝偻病的儿童(6个月至5岁,中位年龄10.5个月)。排除标准为影响吸收的疾病、过去6个月内摄入钙/维生素D制剂、肾功能异常以及非营养性佝偻病。
维生素D3单剂量口服90,000国际单位(A组,n = 55)或300,000国际单位(B组,n = 55)。
根据撒切尔放射学评分标准,通过膝部和腕部X线对佝偻病严重程度进行评分。测量基线血清钙、碱性磷酸酶(SAP)、25(OH)D、甲状旁腺激素(iPTH)水平。在1周、4周和12周进行随访。
主要指标——3个月时的放射学评分。次要指标——3个月时血清25(OH)D、SAP和iPTH水平、临床和生化不良反应。
86名受试者(每组43名)完成了研究。A组放射学评分从6.90降至0.16,B组从6.93降至0.23。两组在基线和随访时25(OH)D、碱性磷酸酶(ALP)和甲状旁腺激素(PTH)水平相似。B组高钙尿症和高钙血症以及维生素D过多症更为常见。未出现临床不良事件。
口服单剂量90,000国际单位维生素D3治疗佝偻病安全有效。